Every few years, the Surviving Sepsis Campaign publishes a document that most of critical care medicine will lean on, argue about, and quietly ignore in equal measure. The 2026 update is no exception: 88 pages, 69 authors, and 129 recommendations distilled from a literature base no single clinician could realistically keep up with alone. On the Critical Care Commute Podcast, Dr. Bram Rochwerg, vice-chair of the guideline panel and a McMaster University intensivist, walked through what changed, what didn’t, and where he personally disagreed with his own committee.
The Honesty Behind the Numbers
Start with a number that reframes how to read this document: of 129 recommendations, only 17 are rated “strong.” The rest are conditional, an accurate reflection of remaining uncertainty in sepsis care. Strong recommendations are meant for the 90–95% of patients where deviation needs a good reason.
Screening and the First Hours
One clear change is a formal move away from qSOFA as a screening tool, it’s a poor performer, and the panel now favors instruments like MEWS instead. The MEWS score is a clinical tool that uses respiratory rate, heart rate, systolic blood pressure, temperature, and level of consciousness to identify patient deterioration, with scores ≥4 requiring urgent review and ≥5 indicating high risk of ICU transfer or mortality. New this cycle is an explicit recommendation to screen for sepsis in the pre-hospital setting, often via paramedic teams, reflecting recognition that the “golden hours” of sepsis care start before a patient reaches the emergency department.
Fluid resuscitation still centers on roughly 30 mL/kg, but the guideline leans hard into individualization rather than treating that figure as a mandate. Notably, there’s now a conditional recommendation for active fluid removal (diuresis or ultrafiltration), once a patient stabilizes post-resuscitation. Blood pressure targets were also refined: the guideline frames a narrower 60–70 mmHg range, with some signal that older adults may benefit from aiming closer to 60 instead of the flat recommendation of 65mmHg.
Lines, Access, and a Generational Divide
Peripheral administration of vasopressors, at low doses, using a larger bore catheter, as proximal as possible, early in a patient’s course, is now supported by growing evidence as safer than commonly assumed. Noninvasive blood pressure monitoring is conditionally endorsed as an alternative in appropriate patients.
These recommendations produced real friction on the panel, invasive monitoring and central access are, for many intensivists, part of what it means to practice critical care. But the data increasingly supports a more selective approach, reserving central and arterial access for patients who are more unstable.
Steroids.
Perhaps the most conceptually important shift is around corticosteroids. The guideline now conditionally recommends hydrocortisone for septic shock, but explicitly not as treatment for “relative adrenal insufficiency,” but rather immune dysregulation, as a broad, imperfect immunomodulator where the underlying problem is often not a hormone deficit but a body responding to its own inflammatory cascade.
Rochwerg sees this as a preview of where sepsis management is heading, toward sub-phenotyping patients by their pathway of immune dysfunction and matching them to targeted therapy, rather than treating sepsis as one disease with one algorithm.
Antibiotics, Stewardship, and Two New “Don’ts”
The one-hour antibiotic benchmark for definite or probable septic shock remains, tempered by acknowledgment that the window is harder to hit in less certain presentations. What’s new is a pair of stewardship-minded recommendations: don’t reach for empiric anaerobic or antifungal coverage unless a patient has actual risk factors for those organisms.
What Didn’t Make the Cut and What Barely Did
Albumin’s recommendation against upfront use continues to strengthen: no clear benefit over crystalloid, at roughly 100 times the cost. Balanced crystalloids like Ringer’s are now favored over normal saline, informed by newer trial data in septic shock populations specifically.
Methylene blue remains an area of genuine promise without enough evidence to act on. Small trials and sound physiologic rationale support its use in refractory septic shock, but the panel explicitly declined to issue a recommendation, choosing instead to wait for larger trials already underway. Rochwerg drew a pointed parallel to the vitamin C era in critical care — an intervention that made physiologic sense, generated enthusiasm, and ultimately didn’t hold up under rigorous testing.
And then there’s the recommendation Rochwerg says he voted against: awake proning for non-intubated patients with respiratory failure. Built almost entirely on COVID-era data, it passed as conditional despite, by his account, a room of intensivists who mostly weren’t practicing it outside that context. It’s a rare moment of a guideline author publicly noting daylight between his own view and the panel’s conclusion, a reminder that consensus documents are consensus, not unanimity.
The Takeaway
What comes through in this conversation isn’t a list of new rules so much as a snapshot of a field working out its uncertainties in public. The 2026 Surviving Sepsis Campaign guideline is less a rulebook than a structured argument, built from imperfect evidence, and real clinical experience.
Leave a Reply